Korean J Helicobacter Up Gastrointest Res.  2014 Dec;14(4):237-241. 10.7704/kjhugr.2014.14.4.237.

Recent Trends of Helicobacter pylori Eradication Therapy: Focusing on First Line Treatment

• Kim KB
• Kim YS

• KMID: 2305125
• DOI: http://doi.org/10.7704/kjhugr.2014.14.4.237

Abstract

Helicobacter pylori infection causes peptic ulcer, gastric cancer and gastric mucosa-associated lymphoid-tissue lymphoma. H. pylori eradication has played a major role in the prevention and treatment of these diseases. The guidelines for the diagnosis and treatment of H. pylori infection in Korea recommends standard triple therapy consisting of proton pump inhibitor, clarithromycin and amoxicillin as the first line eradication therapy and quadruple therapy including bismuth in case of clarithromycin-resistant H. pylori infection. However, the eradication rate of conventional first line therapy of H. pylori infection has been decreasing during the last decade. Recently the eradication rates of standard triple therapy in Korea is reported to be lower than 80% and sometimes even lower than 70% (intention-to-treat). Therefore, the need for new first line eradication regimens has been rising. Sequential therapy, concomitant therapy and tailored therapy have been introduced as new options for first line therapy. However, they have yet to be proven as standard therapy and need further studies.

Keyword

Helicobacter pylori; Eradication

MeSH Terms

Amoxicillin
Bismuth
Clarithromycin
Diagnosis
Helicobacter pylori*
Korea
Lymphoma
Peptic Ulcer
Proton Pumps
Stomach Neoplasms
Amoxicillin
Bismuth
Clarithromycin
Proton Pumps